Financials The Chemours Company

Equities

CC

US1638511089

Diversified Chemicals

Market Closed - Nyse 04:00:02 2024-07-19 pm EDT 5-day change 1st Jan Change
23.48 USD -2.69% Intraday chart for The Chemours Company -4.20% -25.55%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 2,958 4,078 5,469 4,621 4,682 3,496 - -
Enterprise Value (EV) 1 6,175 6,999 7,767 7,134 7,517 6,587 6,525 6,369
P/E ratio -56.5 x 18.8 x 9.32 x 8.39 x -19.7 x - 7.18 x 4.66 x
Yield 5.53% 4.03% 2.98% 3.27% - 4.24% 4.33% 4.46%
Capitalization / Revenue 0.54 x 0.82 x 0.86 x 0.68 x 0.78 x 0.6 x 0.56 x 0.54 x
EV / Revenue 1.12 x 1.41 x 1.22 x 1.05 x 1.25 x 1.14 x 1.05 x 0.99 x
EV / EBITDA 6.05 x 7.96 x 5.92 x 5.24 x 7.41 x 7.5 x 5.88 x 5.21 x
EV / FCF 36.5 x 13 x 14.3 x 16 x 40.4 x -46.2 x 28.4 x 13.6 x
FCF Yield 2.74% 7.72% 6.99% 6.27% 2.47% -2.16% 3.52% 7.36%
Price to Book 4.29 x 5.03 x 5 x 4.11 x 6.36 x 4.95 x 4.1 x 3.2 x
Nbr of stocks (in thousands) 163,501 164,496 162,961 150,918 148,438 148,895 - -
Reference price 2 18.09 24.79 33.56 30.62 31.54 23.48 23.48 23.48
Announcement Date 2/13/20 2/11/21 2/10/22 2/9/23 3/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 5,526 4,969 6,345 6,794 6,027 5,796 6,221 6,432
EBITDA 1 1,020 879 1,313 1,361 1,014 878.4 1,111 1,223
EBIT 1 709 559 996 1,070 707 577 799.6 847
Operating Margin 12.83% 11.25% 15.7% 15.75% 11.73% 9.96% 12.85% 13.17%
Earnings before Tax (EBT) - - - 741 - - 618 953
Net income 1 -52 - 608 578 -238 219 501 772
Net margin -0.94% - 9.58% 8.51% -3.95% 3.78% 8.05% 12%
EPS -0.3200 1.320 3.600 3.650 -1.600 - 3.270 5.040
Free Cash Flow 1 169 540 543 447 186 -142.5 230 468.5
FCF margin 3.06% 10.87% 8.56% 6.58% 3.09% -2.46% 3.7% 7.28%
FCF Conversion (EBITDA) 16.57% 61.43% 41.36% 32.84% 18.34% - 20.71% 38.31%
FCF Conversion (Net income) - - 89.31% 77.34% - - 45.91% 60.69%
Dividend per Share 2 1.000 1.000 1.000 1.000 - 0.9966 1.017 1.048
Announcement Date 2/13/20 2/11/21 2/10/22 2/9/23 3/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 1,575 1,764 1,915 1,777 1,338 1,536 1,643 1,487 1,361 1,350 1,530 1,498 1,396 1,485 1,690
EBITDA 1 307 403 475 363 120 304 324 247 176 193 220 235.2 207.4 276.7 349
EBIT 1 231 329 403 291 46 225 246 171 102 122 153.4 170.6 144 187.1 274.4
Operating Margin 14.67% 18.65% 21.04% 16.38% 3.44% 14.65% 14.97% 11.5% 7.49% 9.04% 10.03% 11.39% 10.31% 12.6% 16.24%
Earnings before Tax (EBT) 1 - - 231 299 - 173 -433 - -71 67 74 86 46 111 198
Net income 1 233 234 201 240 -97 145 -376 - -18 52 60 70 37 90 161
Net margin 14.79% 13.27% 10.5% 13.51% -7.25% 9.44% -22.88% - -1.32% 3.85% 3.92% 4.67% 2.65% 6.06% 9.53%
EPS 2 1.400 1.430 1.260 1.520 -0.6500 0.9600 -2.520 - -0.1200 0.3400 0.4000 0.4600 0.2400 0.5900 1.050
Dividend per Share 2 0.2500 0.2500 0.2500 0.2500 0.2500 0.2500 0.2500 0.2500 - 0.2500 0.2483 0.2483 0.2483 0.2689 0.2705
Announcement Date 2/10/22 5/2/22 7/28/22 10/25/22 2/9/23 4/27/23 7/28/23 10/26/23 3/27/24 4/30/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 3,217 2,921 2,298 2,513 2,835 3,091 3,029 2,873
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 3.154 x 3.323 x 1.75 x 1.846 x 2.796 x 3.519 x 2.727 x 2.349 x
Free Cash Flow 1 169 540 543 447 186 -143 230 469
ROE (net income / shareholders' equity) 49.2% 43.8% 64.2% 67.5% 46.1% 33.2% 52.9% 52%
ROA (Net income/ Total Assets) 5.73% 4.59% 8.31% 9.72% 5.35% 3.51% 5.38% 6.5%
Assets 1 -907.2 - 7,316 5,948 -4,449 6,241 9,309 11,882
Book Value Per Share 2 4.210 4.930 6.710 7.450 4.960 4.740 5.720 7.330
Cash Flow per Share 3.940 - 4.860 4.760 3.690 - - -
Capex 1 481 267 277 307 370 392 447 403
Capex / Sales 8.7% 5.37% 4.37% 4.52% 6.14% 6.76% 7.18% 6.27%
Announcement Date 2/13/20 2/11/21 2/10/22 2/9/23 3/27/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
23.48 USD
Average target price
29.9 USD
Spread / Average Target
+27.34%
Consensus
  1. Stock Market
  2. Equities
  3. CC Stock
  4. Financials The Chemours Company